Below are current clinical trials.19 studies in Brain tumor
(open studies only).
Filter this list of studies by location, status and more.
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to assess the side effects and best dose of ATR kinase inhibitor VX-970 when given together with whole brain radiation therapy for the treatment of patients who have non-small cell lung cancer that has spread from the original (primary) tumor to the brain. VX-970 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving VX-970 together with radiation therapy may be a better treatment for non-small cell lung cancer.
The purpose of this study is to collect and store limited identified surgical waste specimens from skull base tumor cases. We will also collect peripheral blood samples and store PBMC (white blood cells) and serum for each patient.
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this study is to use a nutrient called 18F-FDOPA and PET/CT scan to help determine where and how big the tumor is, as well as how aggressive the tumor is. This will help treating physicians to target diseased areas with higher than standard doses of radiation, in order to improve the effectiveness of radiation in this tumor.
The purpose of this study is to collect adult human blood, cerebrospinal fluid, brain, and spine tissues/fluids at time of surgery in order to conduct future studies of the cellular mechanisms of tissue invasion utilized by brain and spine tumors of the central nervous system (CNS).
Scottsdale/Phoenix, Ariz., Rochester, Minn.
The purpose of this study is to find out more about the side effects of rovalpituzumab tesirine (SC16LD6.5) and what doses of rovalpituzumab tesirine (SC16LD6.5) are safe for people with specific delta-like protein 3-expressing cancers.
This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms and less treatment-induced symptoms compared with standard corticosteroid therapy for patients with symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and improve neurologic impairments in patients with brain radionecrosis following radiosurgery for brain metastases.
Rochester, Minn., Scottsdale/Phoenix, Ariz.
This pilot clinical trial studies fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) in planning surgery in patients with gliomas. New imaging procedures, such as 18F-DOPA-PET scan, may help find gliomas and may help in planning surgery.
This phase I trial studies the side effects and the best dose of wild-type reovirus (viral therapy) when given with sargramostim in treating younger patients with high grade brain tumors that have come back or that have not responded to standard therapy. A virus, called wild-type reovirus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. Sargramostim may increase the production of blood cells and may promote the tumor cell killing effects of wild-type reovirus. Giving wild-type reovirus together with sargramostim may kill more tumor cells.
Aug. 10, 2017
- What you need to know about brain tumors. National Cancer Institute. http://www.cancer.gov/cancertopics/wyntk/brain. Accessed Oct. 4, 2013.
- Adult brain tumors treatment (PDQ): Health professional version. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/healthprofessional. Accessed Oct. 4, 2013.
- Daroff RB, et al. Bradley's Neurology in Clinical Practice. 6th ed. Philadelphia, Pa.: Saunders Elsevier; 2012. https://www.clinicalkey.com. Accessed Oct. 4, 2013.
- Childhood brain and spinal cord tumors treatment overview (PDQ): Health professional version. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/childbrain/healthprofessional. Accessed Oct. 4, 2013.
- Niederhuber JE, et al., eds. Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed Oct. 4, 2013.
- Armstrong TS, et al. Use of complementary and alternative medical therapy by patients with primary brain tumors. Current Neurology and Neuroscience Reports. 2008;8:264.
- Avastin (prescribing information). South San Francisco, Calif.: Genentech Inc.; 2013. http://www.avastin.com/patient/index.html. Accessed Oct. 4, 2013.
- Afinitor (prescribing information). East Hanover, N.J.: Novartis Pharmaceuticals Corp.; 2014. http://www.afinitor.com. Accessed Oct. 4, 2013.
- Temodar (prescribing information). Whitehouse Station, N.J.: Merck & Co. Inc.; 2013. http://www.temodar.com. Accessed Oct. 4, 2013.
- Taking time: Support for people with cancer. National Cancer Institute. http://cancer.gov/cancertopics/takingtime. Accessed Oct. 4, 2013.
- Brain SPOREs. National Cancer Institute. http://trp.cancer.gov/spores/brain.htm. Accessed Oct. 9, 2013.
- Golden AK. Decision Support System. Mayo Clinic, Rochester, Minn. Aug. 2, 2013.
News, connections and conversations for your health